Fonte: European Journal of Medicinal Chemistry. Unidades: FCF, ICB
Assuntos: ANTINEOPLÁSICOS, HIBRIDIZAÇÃO, CÉLULAS CULTIVADAS DE TUMOR, PROTEÍNAS, PURINAS, CITOTOXINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WAITMAN, Karoline de Barros et al. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry, v. 263, p. 1-18 art. 115935, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ejmech.2023.115935. Acesso em: 01 nov. 2024.APA
Waitman, K. de B., Almeida, L. C. de, Primi, M. C., Carlos, J. A. E. G., Ruiz, C., Kronenberger, T., et al. (2024). HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry, 263, 1-18 art. 115935. doi:10.1016/j.ejmech.2023.115935NLM
Waitman K de B, Almeida LC de, Primi MC, Carlos JAEG, Ruiz C, Kronenberger T, Laufer S, Goettert MI, Poso A, Vassiliades SV, Souza VAM de, Toledo MFZJ, Hassimotto NMA, Cameron MD, Bannister TD, Costa-Lotufo LV, Machado Neto JA, Tavares MT, Parise Filho R. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents [Internet]. European Journal of Medicinal Chemistry. 2024 ; 263 1-18 art. 115935.[citado 2024 nov. 01 ] Available from: https://dx.doi.org/10.1016/j.ejmech.2023.115935Vancouver
Waitman K de B, Almeida LC de, Primi MC, Carlos JAEG, Ruiz C, Kronenberger T, Laufer S, Goettert MI, Poso A, Vassiliades SV, Souza VAM de, Toledo MFZJ, Hassimotto NMA, Cameron MD, Bannister TD, Costa-Lotufo LV, Machado Neto JA, Tavares MT, Parise Filho R. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents [Internet]. European Journal of Medicinal Chemistry. 2024 ; 263 1-18 art. 115935.[citado 2024 nov. 01 ] Available from: https://dx.doi.org/10.1016/j.ejmech.2023.115935